

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute, and is not intended to be, an invitation or offer to acquire, purchase or subscribe for, or offer to sell or a solicitation of any offer to buy securities in Hong Kong, the People's Republic of China or elsewhere.

PW MEDTECH GROUP LIMITED

普华和顺集团公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

VOLUNTARY TERMINATION OF THE SUBSEQUENT LISTING OF SICHUAN RUIJIAN MEDICAL ON BEIJING STOCK EXCHANGE

This announcement is made by PW Medtech Group Limited (the “**Company**”) on a voluntary basis.

Reference is made to (i) the relevant announcements of the Company dated May 20, 2024, July 2, 2024, October 2, 2024, December 5, 2024, December 9, 2024, March 25, 2025, June 20, 2025, August 11, 2025, September 30, 2025 and December 30, 2025; (ii) the circular of the Company dated January 21, 2025 (the “**Circular**”); and (iii) the overseas regulatory announcement of the Company dated April 30, 2025, in relation to, among others, the possible major transaction and deemed disposal in relation to the proposed listing of Sichuan Ruijian Medical. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular. As disclosed in the Circular, the NEEQS Quotation was approved by the NEEQ Co., Ltd. and was successfully completed. Further, as disclosed in the relevant announcement of the Company dated March 25, 2025, Sichuan Ruijian Medical has submitted its application for the Subsequent Listing to the Beijing Stock Exchange on the same day. The Board hereby provides the latest update on the Subsequent Listing to its Shareholders.

On March 11, 2026, Sichuan Ruijian Medical, based on a prudent analysis of key factors such as its own business development direction and the current market environment, after careful research, full reasoning and in-depth communication with the sponsor, Sichuan Ruijian Medical has decided to adjust its capital markets strategic plan and intends to voluntarily terminate the application for the Subsequent Listing.

Shareholders and potential investors should note that the voluntary termination of the Subsequent Listing is subject to, among other things, the approvals of the shareholders of Sichuan Ruijian Medical and the Beijing Stock Exchange. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
PW Medtech Group Limited
Yue'e Zhang
Chairman & Chief Executive Officer

Hong Kong, March 12, 2026

As at the date of this announcement, the Board comprises one executive director, namely, Ms. Yue'e Zhang; two non-executive directors, namely Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.